Sourcing comparison · Generic Drugs
Tariff & fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
| Annual import value | Estimated duty & fee savings / year |
|---|---|
| $50,000 | $9,495 |
| $250,000 | $47,475 |
| $1,000,000 | $189,900 |
Savings scale linearly with volume. Enter your exact figure to model it precisely.
Calculate your exact volume →A generic drugs importer's margin increasingly turns on a single field on the entry: country of origin. Goods from India clear at an effective 18%, while China clears the same category at 0% — about $18,990 a year at $100,000 of imports. The importers who win this cycle are the ones treating country of origin as a number to optimise, not a given. The breakdown below itemises both duty stacks so the figure is auditable, not asserted.
Consider what each country's goods actually face at the border. A India origin attracts a 0% Most-Favoured-Nation base duty and a 18% negotiated bilateral rate on its generic drugs, an effective 18% once the $49.74 in processing fees are added. China-made goods carry a 0% Most-Favoured-Nation base duty on its generic drugs, an effective 0% once the $49.74 in processing fees are added. Two charges are origin-blind — the MPF and HMF, together $49.74 on this entry — which is why the entire difference lives in the duty layers. The per-shipment gap comes to $1,899.00 on $10,000 of goods — a clean read on the 18% rate difference. Multiply across your volume and it is near $4,748 for $25,000 and about $18,990 for $100,000 a year. At order level, $25,000 of goods carries roughly $4,748 more duty from India than from China.
Within HTS 3004, generic drugs includes Generic antibiotics, Blood pressure medications, Diabetes drugs, and Cancer generics. Demand for generic drugs is broad and price-sensitive, which is exactly why a duty wedge of this size reshapes who can supply the US market competitively. India, in Asia-Pacific, ships the US mainly pharmaceutical ingredients, generic drugs, and clothing garments. For India, a negotiated bilateral rate stands in for Section 122, changing the math on generic drugs entries. China, in Asia-Pacific, ships the US mainly consumer electronics, computers servers, and clothing garments. China trades without a special US agreement, so column-1 rates and every surcharge apply to its generic drugs in full. Because both sit in Asia-Pacific, a switch barely changes the freight picture and mostly changes the duty bill. China is surfaced as a credible alternative, not just the cheapest line — it is among the origins a US buyer of generic drugs could realistically qualify. Sourcing diversification has shifted from resilience theatre to margin necessity, and a documented second source like China is how buyers act on it.
Where China is a viable supplier, expect roughly $18,990 at $100,000, rising to about $47,475 at $250,000 and $189,900 at $1,000,000 as volume grows. The comparison is generated by running the same inputs through the tariff engine for each origin, which keeps everything but the duty layers equal. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier. If any price premium from China is smaller than the duty saving, the switch still wins on net landed cost. Before acting, confirm the China supplier classifies under the same HTS heading, can meet your volume and certifications, and faces no product-specific exclusion or quota that shifts the duty. Time the switch with the policy calendar in mind — the post-Section-122 picture can favour a different origin entirely. Open the Tariff Savings Finder to rank every feasible origin for your specific volume.
At $100,000 of annual import value, switching from India to China saves an estimated $18,990 in duties and fees, because the effective tariff rate falls from 18% to 0%. The saving scales linearly with volume. These figures reflect tariff and fee savings only, assuming equal product cost — your actual landed cost also depends on price and freight, which vary by supplier.
China-origin generic drugs is assessed a 0% Most-Favoured-Nation base duty, for an effective 0% duty rate before the Merchandise Processing Fee ($36.55) and Harbor Maintenance Fee ($13.19).
India carries an effective 18% rate versus 0% for China. The gap comes from differences in the base, Section 122, Section 232 and bilateral rates that apply to each origin.
Tariff rates from Tax Foundation, USITC, and Penn Wharton Budget Model. Last verified May 13, 2026.
